Optimer Pharmaceuticals (OPTR), a San Diego, CA biotech, is up 77 cents to $13.74 after the FDA approved Difiicid, a new drug to fight hospital infections. Shares hit a high of $14.70 on the news Friday afternoon. Options action is brisk Tuesday, with 10,000 calls and 2,170 puts traded in the name so far. Jun 15 calls, which are now 9.2 percent out-of-the-money and expire in 17 days, are the most actives. 6,300 traded (62 percent Ask) against 17,878 in open interest. Some of the action might be closing, as the June 15 call is the largest open interest position in the name. Jun12.5 puts and calls are seeing active trading as well. Implied vols in OPTR are down 11 percent to 55 now that the event risk has passed.